Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting DNA Methylation for Treating Triple-Negative Breast Cancer

1 Nov 2019

Abstract excerpt

Triple-negative breast cancer (TNBC) accounts for 15-20% of all invasive breast cancers and tends to have aggressive histological features and poor clinical outcomes. Unlike, estrogen receptor- or HER2-positive diseases, TNBC patients currently lack the US FDA-approved targeted therapies. DNA methylation is a critical mechanism of epigenetic modification. It is well known that aberrant DNA methylation contributes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation
Share to Genomics and Chromatin Dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31755366
DOI: 10.2217/pgs-2019-0078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting DNA Methylation for Treating Triple-Negative Breast CancerPMID 31755366Read ↗

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesSemantic proximity Read ↗

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical valueSemantic proximity Read ↗

The Role of Methylation in Breast Cancer Susceptibility and Treatment.Semantic proximity Read ↗

Epi-drugs as triple-negative breast cancer treatmentSemantic proximity Read ↗

The DNA methylation landscape of primary triple-negative breast cancerSemantic proximity Read ↗

Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast CancerSemantic proximity Read ↗

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancerSemantic proximity Read ↗

Molecular Basis of Triple Negative Breast Cancer and Implications for TherapySemantic proximity Read ↗

Epigenetics of Triple-Negative Breast Cancer via Natural CompoundsSemantic proximity Read ↗

HDAC Inhibitors for the Therapy of Triple Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.